Advanced Search

 

Study ID Status Title Patient Level Data
T3508605 Completed Clinical efficacy of fluoride toothpastes using an in situ caries model
TDC106220 Completed A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered with 0.25mg Dutasteride Compared with 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
TDC106222 Completed An open label study to evaluate the impact of novel fixed-dose testosterone/dutasteride combinations on the relative bioavailability of the individual dutasteride and testosterone components
TMT106386 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects with Social Anxiety Disorder Study Listed on ClinicalStudyDataRequest.com
TMT106468 Completed A 12 week, randomised, double blind study evaluating the effects of low dose (10mg) and high dose (80mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by Ultra small Super-Paramagnetic Iron Oxide (USPIO) enhanced carotid Magnetic Resonance Imaging (MRI)
TMT106512 Completed Dopamine D2/D3 receptor agonist and antagonist drug effects on fronto-striatal systems related to compulsive behaviour in healthy volunteers and patients with addictive and compulsive disorders
TOC100224 Completed An observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Fusidic acid cream Applied Three Times daily for 7 days in the Treatment adult and paediatric subjects with Impetigo Study Listed on ClinicalStudyDataRequest.com
TOC103469 Completed A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment versus Placebo Ointment Applied Twice Daily for 5 days in the Treatment of Adults and Paediatric Subjects with Impetigo. Study Listed on ClinicalStudyDataRequest.com
TOC106489 Completed An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months Study Listed on ClinicalStudyDataRequest.com
TOC110977 Completed A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects with SITL Study Listed on ClinicalStudyDataRequest.com
TPD102031 Completed A Randomised, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Ten Day Repeat Topical Applications of GW842470X cream on the Skin of Patients with Atopic Dermatitis
TPD103280 Completed Randomised, double-blind, placebo-controlled study of topical GW842470X formulation in adults with moderate atopic dermatitis
TPL102357 Completed A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor agonist, SB-497115-GR, when administered as 30, 50, and 75mg once daily for 12 weeks in subjects with chronic hepatitis C-related thrombocytopenia who are potential candidates for antiviral treatment with pegylated interferon and ribavirin.
TPL103922 Completed Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin)
TPL104054 Terminated Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures
TPL108390 Completed Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin)
TRA100773 Completed A double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor agonist, administered at 30, 50 and 75 mg as oral tablets once-daily for 6 weeks to adult male and female subjects with refractory, chronic immune thrombocytopenic purpura
TRA102537 Completed A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic ITP.
TRA103452 Completed An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral dose of 50mg Eltrombopag in Healthy Subjects and in Volunteers with Mild, Moderate or Severe Hepatic Impairment
TRA104412 Completed An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50 mg [SB-497115] in Healthy Subjects and in Subjects with Mild, Moderate, or Severe Renal Impairment
TRA105325 Completed EXTEND (Eltrombopag Extended Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study.
TRA106914 Completed A phase I, double-blind, placebo and observer-blind positive controlled, randomized, parallel group study in healthy subjects to investigate the photoirritant potential of eltrombopag
TRA108057 Completed An Open-label repeat dosing study of eltrombopag olamine (SB-497115-GR) in adult subjects, with chronic idiopathic thrombocytopenic purpura (ITP)
TRA108132 Completed LENS – Long-term Eltrombopag Observational Study - A long term observational ocular safety follow-up study in adults who have received study medication (SB-497115-GR / eltrombopag olamine or placebo) in a phase II or III clinical study evaluating eltrombopag
TRA110087 Completed Eltrombopag Pediatric Formulation Taste Testing in Healthy Adult Volunteers

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.